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In Brief
Huang, Tailor, et al. show that
neuroepithelial stem (NES) cells derived
from normal induced pluripotent stem
cells (iPSCs) provide a renewable human
cell-based resource to evaluate genetic
mutations in medulloblastoma.
Misexpression of MYCN in both
otherwise-normal NES cells and
PTCH1+/NES cells derived frompatients
with Gorlin syndrome each generated
medulloblastoma in mice.c.
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(Affiliations continued on next page)SUMMARY
Human neural stem cell cultures provide progenitor
cells that are potential cells of origin for brain can-
cers. However, the extent to which genetic predis-
position to tumor formation can be faithfully
captured in stem cell lines is uncertain. Here, we
evaluated neuroepithelial stem (NES) cells, repre-
sentative of cerebellar progenitors. We transduced
NES cells with MYCN, observing medulloblastoma
upon orthotopic implantation in mice. Significantly,
transcriptomes and patterns of DNA methylation
from xenograft tumors were globally more represen-
tative of human medulloblastoma compared to a
MYCN-driven genetically engineered mouse model.
Orthotopic transplantation of NES cells generated
from Gorlin syndrome patients, who are predis-Cell Stem Cell 25, 433–446, Sept
This is an open access article undposed to medulloblastoma due to germline-mutated
PTCH1, also generated medulloblastoma. We engi-
neered candidate cooperating mutations in Gorlin
NES cells, with mutation of DDX3X or loss of GSE1
both accelerating tumorigenesis. These findings
demonstrate that human NES cells provide a potent
experimental resource for dissecting genetic causa-
tion in medulloblastoma.
INTRODUCTION
Neural stem cell culture systems could potentially advance our
understanding of human brain development and disease
(Gage, 2000). The capture of self-renewing neural progenitor
cells in vitro provides scalable cell populations for biochemical
or genetic studies. Importantly, neural stem cells can be geneti-
cally manipulated or differentiated in a controlled environmentember 5, 2019 ª 2019 The Authors. Published by Elsevier Inc. 433
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in human brain.
It has been postulated that brain tumors could develop from
neural progenitors that deviate from their developmental pathway
(Reya et al., 2001). Ex vivo culture of cell populations that are
susceptible to tumorigenesis may provide insight into how neural
progenitors become malignant (Koso et al., 2012; Pollard et al.,
2009). A specific subpopulation of long-term neuroepithelial
stem (NES) cells can be captured from human pluripotent stem-
cell-derived neural rosettes and propagated long-term in culture
(Falk et al., 2012; Koch et al., 2009). These cells maintain neuro-
epithelial properties in culture; the expression of rosette-stage-
specific markers such as SOX1, PLZF1, DACH1, and MMNR1;
and high neurogenic potency. They exhibit hindbrain regional
identity, including expression ofGBX2 andKROX20, andmaintain
responsiveness to ventral and dorsal cell fate cues in a similarway
to the developing neuroepithelium (Koch et al., 2009). Further-
more, stem cells expanded directly from the rostral hindbrain
neuroepithelium of 5- to 6-week human fetuses show chara-
cteristics similar to human induced pluripotent stem cell (iPSC)-
derived NES cells, suggesting that these cells are indeed
representative of neuroepithelial progenitors in the cerebellar
primordium (Tailor et al., 2013). NES cells maintain potency for
the cerebellar lineage both in vitro and following orthotopic trans-
plantation, including differentiation to cerebellar granule neural
precursor (GNP) cells (Tailor et al., 2013). Moreover, they are scal-
able, genetically stable after long-term passages, and amenable
to gene editing and drug screening platforms (Danovi et al.,
2010; Falk et al., 2012;McLaren et al., 2013). However, the tumor-
igenic potential of hindbrain NES cells in the context of tumor-
predisposing mutations has not yet been explored.
The rostral hindbrain neuroepithelium (rhombomere 1) com-
prises two major germinal zones that generate cerebellar cells.
The ventricular neuroepithelium lies at the roof of the developing
fourth ventricle and harbors precursors of GABAergic Purkinje
neurons, Golgi and Lugaro interneurons. By contrast, the upper
rhombic lip is located at the interface between rhombomere 1
and the roof plate and generates all the glutamatergic cells of
the cerebellum, including cerebellar GNP cells (Millen and Glee-
son, 2008; Wang and Zoghbi, 2001; Wingate and Hatten, 1999).
GNP cells are thought to be precursors of medulloblastoma, a
common malignant brain tumor of childhood and young adults
(reviewed in Northcott et al., 2019). GNP cells proliferate exten-
sively in the external granule layer (EGL) of the post-natal brain in
response to Sonic Hedgehog (SHH) ligand, a major regulator of434 Cell Stem Cell 25, 433–446, September 5, 2019cerebellar development (Dahmane and Ruiz i Altaba, 1999;
Wechsler-Reya andScott, 1999). SHH signaling occurs following
interaction of the SHH ligand with PTCH1 receptor, which
de-represses Smoothened (SMO) and activates downstream
target genes (Hooper and Scott, 2005). Aberrations in SHH
signaling are well described in medulloblastoma. In particular,
inactivating mutations in the PTCH1 gene leading to constitutive
activity of SMO are found in 25% of medulloblastoma (Cavalli
et al., 2017; Northcott et al., 2017).
A germlinemutation inPTCH1 is responsible for an autosomal-
dominant, tumor-prone condition, Gorlin syndrome (also known
as nevoid basal cell carcinoma syndrome) (Hahn et al., 1996;
Johnson et al., 1996). Patients with this syndrome develop mul-
tiple basal cell carcinomas of the skin and are also predisposed
to medulloblastoma. Analogously, 15% of Ptch1+/ transgenic
mice also develop medulloblastoma (Goodrich et al., 1997).
Pre-neoplastic lesions can be identified in the EGL of over
50%of thesemice in early post-natal life (Oliver et al., 2005), sug-
gesting that the GNP cell population is particularly susceptible
to the effects of SHH overactivity. Conditional knockout of
Ptch1 in GNP cells led to the formation of medulloblastoma in
all mice by 3 months of age, confirming that GNP cells are sus-
ceptible to oncogenic transformation in the context of SHH
overactivity (Yang et al., 2008). Interestingly, Ptch1 deletion in
precursors of GNP cells located in the ventricular zone of the
dorsal hindbrain also initiated medulloblastoma (Li et al., 2013).
Similar results have been observed with overexpression of
Smo in multipotent cerebellar progenitors (Sch€uller et al., 2008).
We hypothesized that NES cells, as progenitors of the cere-
bellar primordium with competence for generation of GNP cells,
could provide a human model system to study medulloblastoma
initiation and development. We tested this idea, first by trans-
ducing NES cells with MYCN and second by deriving NES cells
from patients with Gorlin syndrome, bearing germline mutations
in PTCH1, and in each case performing orthotopic transplanta-
tion in mice. We then explored the opportunity for functional vali-
dation of candidate drivers of medulloblastoma that co-occur
with PTCH1 mutations.
RESULTS
MYCN Drives Transformation of Normal Human
iPSC-Derived NES Cells to SHH Medulloblastoma
We first asked whether neuroepithelial stem (NES) cells can
be transformed into brain-tumor-initiating cells by a known driver
Figure 1. MYCN Drives Transformation of
NES Cells to Medulloblastoma
(A) Schematic showing differentiation of iPSCs to
NES cells, transduction with FLAG-MYCN, and
orthotopic implantation into mice.
(B) Western blot showing misexpressed MYCN in
normal WTC10 NES cells.
(C) Empty vector and MYCN NES cells were
treated with 5-ethynyl-20-deoxyuridine (EdU) for
1 h and analyzed via flow cytometry. MYCN NES
cells show increased EdU incorporation and
S-phase fraction. Data are presented as mean ±
SEM; *p < 0.05 (t test).
(D) CyQuant Direct cell proliferation analysis
showing increased proliferation in MYCN NES
cells. Data are presented asmean ± SEM; *p < 0.05
(t test).
(E) Kaplan-Meier survival curve of mice injected
with empty vector and MYCN NES cells (n = 4).
p = 0.004 (log-rank test).
(F) (Left) Low magnification (503) of H&E stain-
ing of WTC10 MYCN tumors showing implanted
MYCN NES cells expanding and distorting the
mouse cerebellum and invading down Virchow-
Robin spaces (arrow). (Middle) High magnifica-
tion (4003) of H&E staining revealing anaplastic
features including frequent mitoses (arrows),
cell-cell wrapping (black arrowhead), promi-
nent nuclei (red arrowhead), and karyorrhexis
(red arrow) characteristic of large cell and/or
anaplastic medulloblastoma. (Right) Immuno-
histochemical staining for synaptophysin (SYP)
highlighting neuroblastic pseudorosettes. Scale
bars represent 200 mm for 503 images and
20 mm for 4003 images.
See also Figures S1 and S2 and Tables S1, S4,
and S6.of medulloblastoma. Amplification of MYCN correlates with
high-risk SHH medulloblastoma, and MYCN can drive medullo-
blastoma in germline and non-germline genetically engineered
mouse models (GEMMs) (Swartling et al., 2010; 2012). Human
iPSCs derived from keratinocytes of a karyotypically normal
adult (WTC10) using episomes (Hayashi et al., 2016) were con-
verted into NES cells as described previously (Falk et al., 2012;
Koch et al., 2009) and retained a normal karyotype. Subse-
quently, NES cells were transduced with FLAG-tagged MYCN
(Figures 1A and 1B), leading to increased proliferation and a
higher proportion of cells in S phase compared to NES cells
transduced with empty vector (Figures 1C and 1D). We im-
planted empty vector control and MYCN NES cells orthotopi-
cally in immunocompromised mice.MYCN NES cells generated
tumors between 42 and 57 days post-injection (Figure 1E).
Tumors extracted from cerebellum were transplantable, indi-
cating malignancy. Histological analysis revealed an embryonal
neoplasm with anaplastic features and immunopositive for
synaptophysin, a neuronal marker characteristic of human me-
dulloblastoma, and for FLAG-tagged MYCN (Figures 1F, S1A,
and S1C). Although human pluripotent stem cells have been
described to spontaneously acquire dominant-negative p53
mutations leading to basal expression of p53 (Merkle et al.,2017), p53 was undetectable by immunohistochemical analysis
(Figure S1B and S1C).
Next, we comparedmolecular characteristics of tumors derived
from MYCN NES cells (referred as WTC10 MYCN tumors) with
human medulloblastoma patient tumors. GEMMs have been pre-
viously reported to lackDNAmethylation changes found in human
medulloblastoma (Diede et al., 2013). Using Illumina methylation
arrays, we identified 66 differentially methylated regions (DMRs)
comparing human patient SHH medulloblastoma (amplified for
MYCN) to normal cerebellum, whereas 130 DMRs were identified
in WTC10 MYCN tumors (data not shown). The majority of these
DMRs were hypermethylated in both sets of tumors. WTC10
MYCN tumors showed similar focal changes in methylation in
regions that overlapped 41% (27/66) of the DMRs found in
medulloblastoma tumors from patients (Figure 2A).
We then performed RNA sequencing (RNA-seq) and differential
gene expression analysis of WTC10 MYCN tumors and parental
NES cells. Among the 10 most upregulated genes in WTC10
MYCN tumors compared to NES cells (Table S1), genes previ-
ously linked to cancer progression and malignancy include AVP,
BARHL1, HELT, and LMX1A (Po¨schl et al., 2011; Sun et al.,
2007, 2017; Tsai et al., 2013). Global transcriptome analysis also
indicated thatWTC10MYCN tumors resembledmedulloblastomaCell Stem Cell 25, 433–446, September 5, 2019 435
Figure 2. WTC10 MYCN Tumors Align with
SHH Medulloblastoma
(A) Genomic DNA was extracted from WTC10
MYCN tumors and analyzed via Illumina methyl-
ation arrays. Differentially methylated regions
(DMRs) relative to normal human cerebellum were
identified in SHH medulloblastoma (MB) from
patients with MYCN-amplified tumors (top) and
compared with WTC10 MYCN tumors (bottom).
The complexity of overall methylation differences
(comparing normal cerebellum with each tumor
type) was similar in WTC10 MYCN tumors and
human medulloblastoma tumors, contrasting
a published report comparing GEMM models
(including MYCN-driven GEMMs) with human
tumors (Diede et al., 2013).
(B) Comparing transcriptomes of WTC10 MYCN
tumors with other pediatric brain tumors using prin-
cipal component analysis (PCA) showed WTC10
MYCN tumors aligned best with medulloblastoma.
(C and D) Comparison of transcriptomes of human
WTC10 MYCN tumors and murine MYCN-driven
GEMM tumors (GTML, Swartling et al., 2010) with
four major subgroups of medulloblastoma using
(C) PCA and (D) support vector machine (SVM)
classification. WTC10 MYCN tumors aligned with
SHH subgroup, whereas GTML aligned with group
3medulloblastoma. For SVM, colors indicate class
prediction probabilities (blue, low; red, high), and
asterisks denote the predicted class.
See also Figures S2 and S7 and Tables S1, S4,
and S6.more closely than normal brain and other pediatric brain tumors
(glioblastoma, pilocytic astrocytoma, and ependymoma; Figures
2B and S2A).
Previously, we generated a GEMM of medulloblastoma driven
by misexpression of MYCN (referred as GTML) (Swartling et al.,
2010). The transcriptome of GTML GEMM tumors aligned with
group 3 medulloblastoma, a subgroup in which patient tumors
commonly amplify CMYC and only rarely amplify MYCN (North-
cott et al., 2017). In contrast, WTC10 MYCN tumors clustered
with SHH medulloblastoma (Figures 2C, 2D, and S2B). In sup-
port of WTC10 MYCN tumors representing SHH medulloblas-
toma, WTC10 MYCN tumors, compared to parental NES cells,
showed increased expression of ATOH1, a marker of GNP cells,
a cell of origin for SHH medulloblastoma (Table S1). Thus, the
human stem cell-based model of medulloblastoma showed
greater similarity to the relevant primary tumor, as compared to
a tumor created in mouse cells using the same oncogenic driver.
Human iPSCs from Patients with Gorlin Syndrome
Next, we explored if NES cells with mutant PTCH1 would
generatemedulloblastoma.Mutation ofPTCH1 occurs frequently
in SHH medulloblastoma (Cavalli et al., 2017; Kool et al., 2014;
Northcott et al., 2017), and Ptch1+/ drives medulloblastoma in
mice (Goodrich et al., 1997). To determine whether PTCH1 loss
also generates medulloblastoma in a human stem cell system,
we isolated keratinocytes from a healthy control (KTM1, referred
as control) and from two different patients with Gorlin syndrome436 Cell Stem Cell 25, 433–446, September 5, 2019(KAS537 and KAS573 referred as Gorlin 1 and Gorlin 2, respec-
tively; Figures S3A and S3B), both of whom were predisposed
to medulloblastoma due to heterozygous germline mutations in
PTCH1 (Cowan et al., 1997; Hahn et al., 1996; Johnson et al.,
1996; Wu et al., 2017). Keratinocytes from both Gorlin patients
had distinct nucleotide insertions within an exon of one PTCH1
allele (1762dupG for Gorlin 1 and 1925dupC for Gorlin 2; Fig-
ure S3B), resulting in a frameshift and premature STOP codon
(V588G_fsX39 for Gorlin 1, P643T_fsX11 for Gorlin 2, Figure S3B).
We used Sendai virus to generate iPSCs, confirmed by expres-
sion of pluripotent markers NANOG, OCT4, and SOX2 (Figures
S3C and S3D). The Sendai virus antigen could not be detected
by immunofluorescence in the clonal iPSC lines after five pas-
sages (data not shown). When differentiated to embryoid bodies,
both Gorlin iPSC lines showed expression of markers for neuro-
ectoderm (SOX1 and TUJ1), mesoderm (TBRA), and endoderm
(SOX17) (Figure S3E). We next implanted Gorlin iPSCs into the
kidney capsule of immunocompromised mice and obtained tera-
tomas expressing markers of all three germ layers (Figure S3F).
These results validated that Gorlin iPSC showed pluripotency.
Gorlin NES Cells Display Neural Characteristics with
Enhanced Proliferation and SHH Signaling
We generated NES cells from Gorlin iPSC (Figure S3G). Similar to
control NES cells, bothGorlinNES cells expressed neuralmarkers
(NESTIN, SOX2, SOX1, andPAX6)while suppressing pluripotency
markers (OCT4 and NANOG; Figure 3A). Importantly, NES cells
Figure 3. Gorlin NES Cells Display Neural
Characteristics with Enhanced Proliferation
and SHH Signaling
(A) Similar to Control NES cells, Gorlin NES cells
expressed NES cell-related markers (NESTIN,
SOX1, SOX2, and PAX6), but not pluripotency
markers (OCT4 and NANOG). Scale bars represent
20 mm.
(B) Normal karyotypes for both Gorlin NES lines
scored from 20 spreads each.
(C) Control and Gorlin NES cells were treated with
EdU for 1 h and analyzed by flow cytometry.
No significant differences were seen in cell-cycle
profile of each cell line. Data are presented as
mean ± SEM.
(D) CyQuant Direct cell proliferation assay of con-
trol and Gorlin NES cells show both Gorlin NES cell
lines grew faster than control NES cells. Data are
presented as mean ± SEM. *p < 0.05 (t test).
(E) RT-qPCR quantitation of GLI1 mRNA expres-
sion in Control and Gorlin NES cells.
(F) RT-qPCRquantitation ofGLI1mRNAexpression
in Control and Gorlin NES cells untreated or treated
with SHH ligand (800 ng/mL) for 2 days. Gorlin 1
NES cells show modestly increased sensitivity to
stimulation with SHH ligand compared with control
NES cells. Data are presented as mean ± SEM.
See also Figure S3 and Table S2.from both Gorlin iPSC lines retained a normal karyotype (Fig-
ure 3B). Cell-cycle profiles were not different between normal
and Gorlin NES cells (Figure 3C); however, both Gorlin lines
showed a proliferative advantage in the CyQuant Direct cell prolif-
eration assay as compared to control (Figure 3D). Gorlin NES cells
maintained expression of neuroepithelial stage (PLZF1 and
MMNR1) and hindbrain (GBX2) markers, similar to NES cells
derived from fetal hindbrain (Tailor et al., 2013) (Figure S3H).
Despite heterozygosity for PTCH1, Gorlin NES cells did not
show a basal increase in abundance of the SHH downstream
target GLI1 (Figure 3E). In response to stimulation with SHH
ligand, one of two Gorlin NES cells (Gorlin 1) showed a modest
increased abundance of GLI1 mRNA compared to control NES
cells (Figure 3F). These data show that Gorlin NES cells had a
modest growth advantage and may be more sensitive to SHH
ligand stimulation compared to control NES cells.
Gorlin NESCells Generate SHHMedulloblastoma In Vivo
We investigated whether Gorlin NES cells could generate tumors
in vivo. Control NES cells and NES cells from both Gorlin patientsCell Stemwere injected orthotopically into hind-
brains of immunocompromisedmice (Fig-
ure 4A). Mice developed signs of tumor
between 102 and 206 days for Gorlin 1
and 254 and 360 days for Gorlin 2 NES
cells (Figure 4B). Luminescence imaging
revealed that both Gorlin 1 and Gorlin 2
NES cells xenografted equally well, sug-
gesting the difference in penetrance and
latency was due to the proliferative
advantage of Gorlin 1 NES cells (data
not shown; Figure 3D). To further investi-gate differences between Gorlin 1 and Gorlin 2 NES cells, we
performed RNA-seq analysis on both Gorlin NES cell lines.
Among the 10 most upregulated genes in Gorlin 1 NES cells
compared to Gorlin 2 NES cells, the genes linked to tumor
growth and malignancy that might contribute to the difference
in latency included CYP24A1, FZD10, and HIST1H3C (Decock
et al., 2012; Shiratsuchi et al., 2017; Terasaki et al., 2002) (Table
S2). Another possible explanation for the increased penetrance
fromGorlin 1 NES cells is due to significantly reduced expression
of PTCH2 (>4-fold) in Gorlin 1 NES cells compared to Gorlin 2
NES cells (Table S2). Loss of one or both copies of Ptch2 has
been shown to accelerate tumorigenesis in Ptch1+/ mice (Lee
et al., 2006).
H&E staining revealed an embryonal neoplasm with mild to
moderate nuclear pleomorphism and frequent mitoses charac-
teristic of medulloblastoma (Marshall et al., 2014) (Figure 4C).
Immunohistochemistry showed abundant expression of synap-
tophysin (Figure 4C). RNA-seq analysis aligned Gorlin 1 tumors
with human SHH medulloblastoma as compared to other sub-
types of medulloblastoma and other types of pediatric brainCell 25, 433–446, September 5, 2019 437
Figure 4. Gorlin NES Cells Generate SHH
Medulloblastoma In Vivo
(A) Schematic of differentiation of control and
Gorlin iPSC toward NES cells, implantation into
hindbrains of immunocompromised mice, and
generation of tumors.
(B) Kaplan-Meier survival curve of mice (n = 10)
implanted with each cell line. p < 0.0001 (log-rank
test).
(C) Gorlin tumors showed a hypercellular embry-
onal neoplasmwith indistinct cell borders, frequent
mitoses (arrows), prominent nuclei (red arrow-
head), karyorrhexis (red arrow), and synaptophysin
(SYP) positivity. Scale bars represent 20 mm.
(D) Comparison of transcriptomes of Gorlin 1
tumors with other pediatric brain tumors using
(top) PCA and (bottom) SVM classification. Gorlin 1
tumors align with medulloblastoma.
(E) Comparison of transcriptomes of Gorlin 1
tumors with four major subgroups of medullo-
blastoma using (top) PCA and (bottom) SVM
classification. Gorlin 1 tumors aligned with SHH
subgroup. For SVM, colors indicate class predic-
tion probabilities (blue, low; red, high), and aster-
isks denote the predicted class.
See also Figures S4 and S7 and Tables S2, S5,
and S7.tumors (Figures 4D, 4E, S4A, and S4B). Similar to the WTC10
MYCN tumors, Gorlin 1 tumors showed elevated expression
of the GNP cell marker ATOH1 compared to the Gorlin 1
NES cells (Table S2). Thus, Gorlin tumors resembled SHH
medulloblastoma.
Human NES Cells Are Not Committed to the GNP
Lineage
Since the WTC10 MYCN and Gorlin tumors both aligned with
SHH medulloblastoma, we sought to determine whether NES
cells were committed or ‘‘primed’’ to be in a GNP-like state.
We first compared the transcriptomes of WTC10 NES cells, Gor-
lin 1 NES cells, and Gorlin 2 NES cells with mouse GNPs (Carter
et al., 2018). Hierarchical clustering analysis showed the tran-
scriptome profiles of all three NES cells were distinct from
GNPs (Figure 5A). Next, for each NES cell line, we either
maintained undifferentiated, differentiated spontaneously, or
differentiated directly with Wnt3a and GDF7, factors known to
stimulate expression of the GNP marker ATOH1 (Tailor et al.,
2013). Upon stimulation of NES cells with Wnt3a and GDF7,
analysis by RT-qPCR revealed a substantial increase in expres-
sion of ATOH1 compared to spontaneously differentiated or438 Cell Stem Cell 25, 433–446, September 5, 2019undifferentiated NES cells (Figure 5B).
Thus, while NES cells clearly have the
capacity to generate GNPs, they are not
committed to that lineage.
Mutation of DDX3X and GSE1, but
Not KDM3B, Accelerates
Tumorigenesis in Gorlin 1 NESCells
We then asked whether the Gorlin NES
cell model could be used to test candi-date genetic drivers. Sporadic mutation of PTCH1 occurs mainly
in adult medulloblastoma (Cavalli et al., 2017; Kool et al., 2014;
Northcott et al., 2017). Among these adult patients, co-occurring
mutations are found commonly in candidate genes, including
DDX3X, an RNA helicase; genetic suppressor element 1
(GSE1), a coiled-coiled protein known to interact with HDAC1
(Bantscheff et al., 2011); and lysine demethylase 3B (KDM3B),
a demethylase with both tumor-suppressive and tumor-promot-
ing effects (Kim et al., 2012; Xu et al., 2018). Whereas DDX3X
mutations are always missense, mutations in GSE1 and
KDM3B are typically frameshifts, nonsense, or deletions (Jones
et al., 2012; Kool et al., 2014; Northcott et al., 2012; Pugh
et al., 2012; Robinson et al., 2012).
Mutations inDDX3X typically occur within its twoRNA helicase
domains. In SHH medulloblastoma, the most frequent muta-
tions at the N-terminal and C-terminal helicase domains are
DDX3XR351W and DDX3XR534S, respectively (Kool et al., 2014;
Northcott et al., 2017). To evaluate effects of these mutations,
we misexpressed FLAG-tagged DDX3XWT, DDX3XR351W, or
DDX3XR534S at similar levels in Gorlin 1 NES cells (Figure 6A).
While NES cells with mutant DDX3X did not exhibit altered pro-
liferation in vitro (Figures 6B and 6C), mutantDDX3X accelerated
Figure 5. Human NES Cells Are Not Committed to the GNP Lineage
(A) Hierarchical clustering heatmap showing human WTC10 NES and both
Gorlin NES cells have transcriptome profiles distinct frommouse GNPs (Carter
et al., 2018).
(B) WTC10 NES cells and both Gorlin NES cells were differentiated sponta-
neously or stimulated withWnt3a (20 ng/mL) and GDF7 (100 ng/mL) for 2 days.
Analysis by RT-qPCR shows stimulation with Wnt3a and GDF7 substantially
increasedGNPmarkerATOH1 compared to spontaneously differentiated cells
and parental NES cells. Data are presented as mean ± SEM.tumorigenesis in vivo (Figure 6D). Principal component analysis,
support vector machine, and hierarchical clustering show the
DDX3X mutant tumors aligned with SHH medulloblastoma (Fig-
ures 6E, 6F, and S5A). Among the 10 most upregulated genes in
Gorlin 1 DDX3XR351W tumors (compared to Gorlin 1 tumors),
genes previously implicated in tumor growth and malignancy
include HOXA3, HOXB3, KRT6A, and S100A9 (Chen et al.,
2013; Inanc et al., 2014; Lim et al., 2016; Zhang et al., 2018) (Ta-
ble S3). Among the 10 most upregulated genes in Gorlin 1
DDX3XR534S tumors (compared to Gorlin 1 tumors), genes previ-
ously linked with cancer include DDX43, KRT7, HOXB3, and
NNAT (Ambrosini et al., 2014; Huang et al., 2016; Lindblad
et al., 2015; Siu et al., 2008) (Table S3). These experiments vali-
date DDX3X mutations as drivers of SHH medulloblastoma.
Expression of GSE1 and KDM3B correlates inversely with sur-
vival in patients with medulloblastoma (Figure S6A). Therefore,
we created lentiviral CRISPR/Cas9 plasmids targeting GSE1 orKDM3B to generate indels in each gene (Figure S6B). Transduc-
tion of Gorlin 1 NES cells followed by selection with puromycin
resulted in cells with frameshift mutations in both genes, as
well as decreased levels of GSE1 and KDM3B proteins (Fig-
ure 7A). Amplicon sequencing of the target regions (50,000 reads
each) revealed mutation frequencies of 96.7% (69.8% for frame-
shift) forKDM3B and 99.2% (87.9% for frameshift) forGSE1 (Fig-
ures S6C and S6D). Neither loss of GSE1 nor loss of KDM3B
significantly affected proliferation in Gorlin 1 NES cells (Figures
7B and 7C). Next, we tested whether either of these mutations
influenced tumorigenesis in vivo. We injected each Gorlin NES
cell line (transduced with Ctrl single guide RNA [sgRNA], GSE1
sgRNA, or KDM3B sgRNA) into hindbrains of immunocompro-
mised mice. Targeting of GSE1, but not KDM3B, significantly
decreased the latency of Gorlin 1 tumors (Figure 7D). RNA-seq
analysis of three GSE1 mutant tumors (referred as GSE1/
tumors) shows that the tumors again clustered with the SHH
subgroup (Figures 7E and S5B). Among the 10most upregulated
genes in GSE1/ tumors compared to Gorlin 1 tumors, genes
associated with cancer include CTSG, ELANE, HIST1H3C,
NNAT, PEG3, PRTN3, and RNLS (Alatrash et al., 2017; Decock
et al., 2012; Guo et al., 2016; Houghton et al., 2010; Hu et al.,
2018; O¨zata et al., 2017; Siu et al., 2008) (Table S3).
To exclude the possibility that accelerated tumorigenesis
could have resulted as an off-target effect, we re-expressed
wild-type GSE1 (referred as GSE1WT) to determine whether
shortened latency could be rescued. We first generated cell lines
from the GSE1/ tumors. Since these cell lines had stable
expression of Cas9 and sgRNA targeting GSE1, we generated
a plasmid of GSE1WT containing silent mutations at the sgRNA
binding site (Figure S6E). GSE1/ cells were transduced with
theGSE1WT construct with silent mutations or with empty vector.
Rescue of GSE1 expression was confirmed via western blot
(Figure 7F). Empty vector (GSE1/) cells generated tumors be-
tween 60 and 63 days post-implantation, whereas re-expressed
GSE1WT cell lines generated tumors between 67 and 131 days
post-transplant, suggesting GSE1 acts as a tumor suppressor
(Figure 7G). From these analyses, we conclude that mutant
DDX3X and loss ofGSE1 act as drivers of SHHmedulloblastoma
tumorigenesis, while mutations in KDM3B may represent a
passenger.
Genomic Analysis of NES Cell-Derived Tumors
We next performed the comparative genomic hybridization array
(CGH) and whole exome sequencing (WES; 1003 coverage) to
identify copy number changes and mutations in WTC10 MYCN
and Gorlin 1 tumors that may have been acquired in vitro or
in vivo. At the chromosomal level, both sets of tumors lack
copy number changes observed by array CGH (Figure S7). At
the base pair level, the overall mutation rates were quite low.
Each of the three WTC10 MYCN tumors had 0 mutations per
megabase, and the four Gorlin 1 tumors showed 0.6, 6.7, 0.5,
and 16 mutations per megabase (Tables S4 and S5), suggesting
the mutant NES cells did not require additional mutations to
generate tumors. We then investigated the mutation status of
PTCH1 and TP53, as both genes are frequently mutated in
SHH medulloblastoma (Cavalli et al., 2017; Kool et al., 2014;
Northcott et al., 2017), and dominant-negative mutations of
TP53 are known to be acquired in vitro in human pluripotentCell Stem Cell 25, 433–446, September 5, 2019 439
Figure 6. Mutation ofDDX3X in Gorlin 1 NES
Cells Accelerates Tumorigenesis
(A) Western blot of FLAG (DDX3X) expression in
Gorlin 1 NES cells with DDX3XWT, DDX3XR351W, or
DDX3XR534S.
(B) EdU assay of Gorlin 1 NES cells with DDX3X
mutants. Data are presented as mean ± SEM.
(C) CyQuant Direct cell proliferation assay of Gorlin
1 NES cells with DDX3X mutants. Data are pre-
sented as mean ± SEM.
(D) Kaplan-Meier survival curve showing acceler-
ated tumorigenesis in mice implanted with NES
cells harboring DDX3Xmutations (n = 5). p = 0.029
(log-rank test).
(E and F) Comparison of transcriptomes of three
DDX3XR351W and three DDX3XR534S tumors with
the four major subgroups of medulloblastoma us-
ing (E) PCA and (F) SVM classification. PCA and
SVM classification show all six DDX3X mutant
tumors subgrouped with SHH medulloblastoma.
For SVM, colors indicate class prediction proba-
bilities (blue, low; red, high), and asterisks denote
the predicted class.
See also Figure S5 and Table S3.stem cells (Merkle et al., 2017). Interestingly, we identified a SNP
at a coding exon in TP53 (rs1042522, P72R) in both WTC10
MYCN tumors and Gorlin 1 tumors (Tables S4 and S5). This
SNP is unlikely to act as a dominant negative, as (1) it is located
outside of the DNA-binding domain, where most dominant-
negative p53 mutations occur (Petitjean et al., 2007); (2) p53
was not detected by immunohistochemistry (IHC) in WTC10
MYCN tumors (Figures S1B and S1C); and (3) control WTC10
NES cells did not generate tumors (Figure 1C). We confirmed
rs1042522 was present in the parental WTC10 NES cells by
WES and the original iPSC by Sanger sequencing (Table S6;
data not shown) and thus was not acquired during differentiation
to NES cells or upon implantation inmice. The SNP is not consid-
ered damaging according to the International Agency for
Research on Cancer TP53 database (http://p53.iarc.fr) and is
predicted to be benign by ClinVar (https://www.ncbi.nlm.nih.
gov/clinvar/). The minor allele frequency for rs1042522 ranges
from 54% to 66% in multiple databases (Table S6).
As expected,WES revealed the insertionmutation atPTCH1 in
the Gorlin 1 tumors leading to a premature STOP codon (Table
S7). In addition, a frameshift deletion in PTCH2 was identified
at exon 15, likely explaining the reduced expression levels and
at least a contribution to the higher tumor penetrance compared
to Gorlin 2 NES cells (Tables S2 and S7).
A previous report by Zindy and collaborators (Zindy et al.,
2007) showed that SHH medulloblastoma induced by enforced
expression of N-Myc in mouse GNP cells sustained loss of
Ptch1. To address whether human WTC10 MYCN tumors simi-440 Cell Stem Cell 25, 433–446, September 5, 2019larly showed loss of PTCH1, we analyzed
WTC10 MYCN tumors, identifying a SNP
in a coding exon of PTCH1 (rs357564,
P1315L) (Table S4). This SNP was also
detected in the original parental WTC10
NES cells byWES (Table S6) and in iPSCs
by Sanger sequencing (data not shown).ClinVar lists rs357564 as benign, and minor allele frequencies
range from 30%–40% of populations surveyed in similar data-
bases described for the TP53 SNP. Since both the PTCH1
SNP and the TP53 SNP did not produce a tumor in our empty
vector WTC10 NES cells (Figure 1C), both occur at high fre-
quencies in the general population, and (for TP53) the SNP is
located outside the hotspot region for dominant-negative muta-
tions, neither is likely to affect tumorigenesis. Thus, our analysis
suggests the mutations we introduced into NES cells represent
the major drivers of diseases observed.
DISCUSSION
Pediatric embryonal cancers may occur when progenitors har-
bormutations that cause deviation in their normal developmental
program (Northcott et al., 2019). GEMMs have provided support
for this model but show clear differences with human tumor
phenotypes. Here, we demonstrate that defined genetic pertur-
bations in a specific class of human progenitor cells lead to the
formation of a distinct human cancer phenotype.
Medulloblastoma is among the best characterized of all can-
cers genetically. While the overall 5-year survival rate for medul-
loblastoma is 80% (Drezner and Packer, 2016), standard of
care treatment with intracranial surgery, radiation, and intensive
chemotherapy significantly impacts cognition and growth.
Tumors can be divided into four main molecular subgroups
(SHH, WNT, group 3, and group 4), although further genetic
heterogeneity exists within each group (Cavalli et al., 2017;
Figure 7. Knockout of GSE1, but not
KDM3B, in Gorlin 1 NES Cells Accelerates
Tumorigenesis
(A) Western blot showing loss of expression of
GSE1 (top) and KDM3B (bottom) in response to
CRISPR/Cas9 knockout.
(B) EdU assay of Gorlin 1 NES cells with control
(Ctrl), GSE1, or KDM3B sgRNA. Data are pre-
sented as mean ± SEM.
(C) CyQuant Direct cell proliferation assay of Gorlin
1 NES cells with Ctrl, GSE1 or KDM3B sgRNA.
Data are presented as mean ± SEM.
(D) Kaplan-Meier curve showing reduced survival
of mice injected with Gorlin 1 NES cells harboring
GSE1 sgRNA compared with Ctrl sgRNA or
KDM3B sgRNA (n = 5). p = 0.0032 (log-rank test).
(E) PCA (left) and SVM (right) classification showing
three GSE1/ tumors subgrouped with SHH me-
dulloblastoma.
(F and G) GSE1/ cell lines were transduced with
empty vector or the silent mutant GSE1 (GSE1WT).
Both cell lines were (F) analyzed by western blot
analysis and (G) injected into mice (n = 5).
p = 0.0031 (log-rank test).
See also Figures S5 and S6 and Table S3.Northcott et al., 2017). Germline mutation in PTCH1 predisposes
patients to medulloblastoma, with mutation in PTCH1 also
occurring commonly in sporadic disease. In a recent clinical trial
to treat mutant PTCH1 tumors using the SMO inhibitor vismode-
gib, tumors showed regression initially but eventually relapsed
(Robinson et al., 2015). Moreover, no targeted treatments exist
for children with MYCN-amplified SHH tumors, a highly lethal
subtype. Our findings establish two human stem cell-based
genetic models of SHH medulloblastoma that could be used
as tools for genetic screening or drug discovery for targeted
therapies.
Misexpression of MYCN in human NES cells transplanted
orthotopically in mice generated medulloblastoma in vivo.
Amplification ofMYCN is normally found in SHH or group 4 me-
dulloblastoma and rarely in group 3 tumors (Northcott et al.,
2017). Consistent with these associations, transcriptome anal-
ysis of human WTC10 MYCN tumors from NES cells alignedCell Stemclosest to SHH medulloblastoma. In
contrast, the GTML model, our previ-
ously characterized GEMM for me-
dulloblastoma also driven by MYCN,
more closely resembled group 3 medul-
loblastoma (Figures 2C and 2D), a sub-
group of medulloblastoma associated
more commonly with amplification of
CMYC. Furthermore, while GTML tumors
showed much fewer regions of hyperme-
thylation than human medulloblastoma
patient tumors (Diede et al., 2013), the
human WTC10 MYCN tumors exhibited
DMRs at almost half the sites found in
patient-derived tumors (Figure 2A).
Thus, the human WTC10 MYCN tumor
model of medulloblastoma recapitulatesthe specific tumor subtype and epigenetic profile more accu-
rately than the MYCN GEMM.
We then derived iPSCs from patients with Gorlin syndrome
and differentiated them to NES cells. We showed that Gorlin
NES cells recapitulated medulloblastoma predisposition and
generated tumors following orthotropic transplantation. This
model was leveraged to test candidate cooperating factors
found in SHH tumors with somatic mutations in PTCH1.
Missense mutation in the RNA helicase DDX3X and loss of
GSE1 both cooperated with PTCH1 heterozygosity to drive
tumorigenesis, whereas loss of candidate driver KDM3B did
not (Figures 6D and 7D). Thus, we have generated two geneti-
cally distinct models for medulloblastoma using a human stem
cell system, exemplified functional evaluation of candidate
cooperating genes in tumor initiation, and describe new experi-
mental resources for the dissection of cooperative events in
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Interestingly, chromosome copy number and single nucleotide
variation analysis of tumors derived from human NES cells re-
vealed few additional mutations compared to NES cells grown
in vitro (Figure S7; Tables S4 and S5). The low mutation rate sug-
gests the specific genetic manipulations we introduced into the
NES cells were sufficient to drive tumorigenesis. Although both
MYC and PTCH1+/ usually require additional genetic mutations
for transformation, NES cells are a stable and highly proliferative
cell population (Kochet al., 2009), and thus, the genes responsible
for self-renewalcouldconceivablysensitizeNEScells to transform
from only a single genetic event. In contrast, mouse models of
MYCN-drivenmedulloblastoma targetingprogenitors ofNEScells
exhibited copy number alterations at the chromosomal level that
likely cooperated with MYCN to generate tumors (Swartling
et al., 2010; Zindy et al., 2007). Although a previous study found
a population of Nestin-expressing progenitors (NEPs) in mice to
bemoregenomically unstable thanGNPs, theseNEPsareaquies-
cent population and less proliferative than GNPs (Li et al., 2013).
Both NES cells and neural stem cells (NSCs) are multipotent
and have the capacity to generate neurons, astrocytes, and oli-
godendrocytes. However, NES cells have a significantly stronger
tendency to differentiate toward neurons (Koch et al., 2009). This
bias toward neuronal lineages may explain why transformed
NES cells (both Gorlin and MYCN driven) resemble medulloblas-
toma more than other brain tumor types thought to be derived
from glial lineages such as glioblastoma, ependymoma, and
pilocytic astrocytoma (Figures 2B, S2B, 4D, and S4A). Similarly,
the NEPs described by Li et al. are alsomore likely to differentiate
toward neurons, and knockout of Ptch1 in NEPs generated
tumors resembling medulloblastoma (Li et al., 2013). Thus, a
human stem cell-based model of a glial-derived brain tumor
would likely require a cell type other than NES cells.
In addition to the association between Gorlin syndrome and
SHH medulloblastoma, other medulloblastoma subtypes are
also known to develop through genetic predisposition. Patients
with Turcot’s syndrome, who have a germline mutation in the
adenomatous polyposis of the colon (APC) gene (Hamilton et al.,
1995), are predisposed toWNT-subtype medulloblastoma, which
has a more indolent clinical course than SHH-subtype medullo-
blastoma (Northcott etal., 2019).While itwill beof interest tomodel
the precursors of WNT-subtype medulloblastoma via iPSCs
derived from individuals with Turcot’s syndrome, studies in mice
suggest the molecular and clinical differences between medullo-
blastoma subtypes may be due to different developmental cells
of origin in distinct regions of the cerebellum (lower rhombic lip
for WNT, external germinal layer [EGL] for SHH, ventricular zone
or EGL for group 3, and upper rhombic lip or nuclear transitory
zone for group 4; Azzarelli et al., 2018; Gibson et al., 2010; Kawau-
chi et al., 2012; Lin et al., 2016;Pei et al., 2012;Sch€uller et al., 2008;
Yang et al., 2008). Thus, the transcriptome of these various cell
typesmay provide the appropriate environment for specificmuta-
tions to transform the cells tomedulloblastoma andwould explain
why some mutations are specific to a particular subgroup.
These divergent subpopulations of hindbrain cells could be
generated from iPSCs or NES cells that express gene-specific
reporter proteins to further investigate the influence of cellular
origin on human medulloblastoma phenotype. Comparing
isogenic lines that model distinct cells of origin could address
whether mutations occur early at the NES cell stage to direct dif-442 Cell Stem Cell 25, 433–446, September 5, 2019ferentiation down a particular cell lineage or whether mutations
occur after NES cells differentiated to the appropriate cell type.
Although our study showed the NES cells can generate SHHme-
dulloblastoma, these cells were not primed to generate GNP
cells, as the transcriptomes were quite distinct and spontaneous
differentiation of NES cells does not lead to maximal expression
of the GNP marker ATOH1 (Figures 5A and 5B). Instead, NES
cells are prone to generating neurons of different lineages and
have the capacity to generate GNPs.
The modeling of different medulloblastoma subtypes will
have important implications for future targeted therapy. Xeno-
graft models of human medulloblastoma in mice could
be tested with specific genetic or drug therapies developed
through screening of predisposed or transformed stem cells.
In addition, the recapitulation of human medulloblastoma
in vitro and in vivo could lead to methods for halting progression
of premalignant cells. These strategies may help to prevent the
progression of tumors in children and obviate the need for
adjuvant chemotherapy or radiotherapy with the associated
harmful side effects.
In conclusion, we demonstrate that human NES cells with ge-
netic tumor predisposition generate bona fide medulloblastoma.
Using known drivers of disease (PTCH1 andMYCN), we demon-
strate robust generation of SHH-subtype medulloblastoma and
cooperativity between heterozygosity for PTCH1 with mutations
in DDX3X or GSE1. Thus, human NES cell-based models offer
a powerful system for refined analyses of human medulloblas-
toma tumorigenesis, with the prospect of future applications in
screening candidate therapeutic compounds.STAR+METHODS
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Deposited Data
Mouse granule neural precursor transcriptome data https://www.ncbi.nlm.nih.gov/
pubmed/30220501
ENA: PRJEB23051
Raw RNaseq This paper EGAS00001003620
Raw Whole Exome Sequencing This paper EGAS00001003620
Raw amplicon sequencing This paper EGAS00001003620
GTML tumor RNA expression data https://www.ncbi.nlm.nih.gov/
pubmed/22624711
GEO: GSE36594
Human brain tumor expression data https://www.ncbi.nlm.nih.gov/
pubmed/24078694
GEO: GSE50161
Human medulloblastoma tumor subgroup
expression data
https://www.ncbi.nlm.nih.gov/
pubmed/28609654
GEO: GSE85217
Experimental Models: Cell Lines
WTC10 iPSC Conklin Lab https://www.ncbi.nlm.nih.gov/pubmed/27794120
Gorlin 1 iPSC This paper N/A
Gorlin 2 iPSC This paper N/A
WTC10 NES cells This paper N/A
Control NES cells This paper N/A
Gorlin 1 NES cells This paper N/A
Gorlin 2 NES cells This paper N/A
Sai2 NES cells Smith Lab https://www.ncbi.nlm.nih.gov/pubmed/23884946
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Oligonucleotides
GSE1 sgRNA (TTGGAGCGATGGTCACCACG) Integrated DNA Technologies N/A
KDM3B sgRNA (GCAGAACTGGTCCCCAACAT) Integrated DNA Technologies N/A
GSE1 surveyor F (ctgcacgtggctgtcact);
GSE1 surveyor R (actcaacctcgaaagctcca)
Integrated DNA Technologies N/A
KDM3B surveyor F (gctcctgcgatttaccatgt);
KDM3B surveyor R (ccccaatcttcccgttaagt)
Integrated DNA Technologies N/A
GLi1 qPCR F (cagggaggaaagcagactga);
GLI1 qPCR R (Actgctgcaggatgactgg)
Integrated DNA Technologies N/A
GAPDH qPCR F (CCATGGGGAAGGTGAAGGTC);
GAPDH qPCR R (TGAAGGGGTCATTGATGGCA)
Integrated DNA Technologies N/A
Recombinant DNA (plasmids)
pLentiCRISPR v2 Addgene RRID:Addgene_52961
pCDH-CAG-3xFLAG-MYCN-mScarlet-Luciferase This paper N/A
pCDH-CAG-mScarlet-Luciferase This paper N/A
pCDH-CAG-3xFLAG-DDX3X (WT)-EF1a-
Luciferase-Blast
This paper N/A
pCDH-CAG-3xFLAG-DDX3X (R534S)-
EF1a-Luciferase-Blast
This paper N/A
pCDH-CAG-3xFLAG-DDX3X (R351W)-
EF1a-Luciferase-Blast
This paper N/A
pCDH-CAG-3xFLAG-DDX3X (R534S)-
EF1a-Luciferase-Blast
This paper N/A
pCDH-CAG-GSE1 (silent mut)-EF1a- Blast This paper N/A
Software and Algorithms
Chip Analysis Methylation Pipeline
(ChAMP v. 2.6.4)
Morris et al., 2014 https://bioconductor.org/packages/release/
bioc/html/ChAMP.html
Metilene (v. 0.26) J€uhling et al., 2016 https://www.bioinf.uni-leipzig.de/Software/metilene/
Samtools Li et al., 2009 http://samtools.sourceforge.net/
Burrows-Wheeler Aligner Li, H. 2013 http://bio-bwa.sourceforge.net/
Picard tools Broad Institute https://broadinstitute.github.io/picard/
Mutect2 (GATK4) McKenna et al., 2010;
DePristo et al., 2011;
Reble et al., 2017
https://github.com/broadinstitute/gatk/
Varscan2 Koboldt et al., 2012;
Koboldt et al., 2013.
http://varscan.sourceforge.net/
Annovar Wang et al., 2010 http://annovar.openbioinformatics.org/en/latest/
dbSNP Sherry et al., 2001 https://www.ncbi.nlm.nih.gov/snp/
Exome Aggregation Consortium (ExAC) Lek et al., 2016 http://exac.broadinstitute.org/
Exome Sequencing Project (ESP) NHLBI Exome sequencing
project, 2019
https://evs.gs.washington.edu/EVS/
1000 Genomes Project 1000 Genomes Project
Consortium et al., 2015
http://www.internationalgenome.org/
STAR Dobin et al., 2013 https://github.com/alexdobin/STAR
DESeq Love et al., 2014 https://bioconductor.org/packages/release/bioc/
html/DESeq2.html
Conumee Hovestadt et al., 2013 https://www.bioconductor.org/packages/release/bioc/
html/conumee.html
Bowtie2 Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/bowtie2/index.shtml
Script for Metagene projection Tamayo et al., 2007 https://www.ncbi.nlm.nih.gov/pubmed/17389406
(Continued on next page)
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Subread (v 1.5.2) Liao et al., 2013 http://subread.sourceforge.net/
biomaRt (v 2.34.2) Durinck et al., 2005 http://bioconductor.org/packages/release/bioc/html/
biomaRt.html
OtherLEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for reagents may be directed to and will be fulfilled by the Lead Contact, Dr. William A. Weiss
(waweiss@gmail.com).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
Immunocompromised (NOD-scid IL2Rgammanull or NSG) 6-8 week old female mice used for transplantation were purchased from
Jackson Labs. Mice were maintained in the Animal Facility at UCSF. All experiments were performed in accordance with national
guidelines and regulations, and with the approval of the IACUC at UCSF. 300,000 cells in 5uL of NES cell medium were injected
per mouse. Injections were performed using a stereotactic machine starting from lambda 2mm right, 2mm down and 2mm
deep. Mice were euthanized at endpoint, which was either signs of tumor growth (e.g., hunched back, weight loss, head tilt, etc)
or 1 year post transplantation.
iPSC culture
Male WTC10 iPSC (Hayashi et al., 2016) were maintained on GelTrex coated 6-well plates in mTeSR1 media in a humidified 37C
incubator with 5% CO2. Cells were passaged every 4-5 days using Accutase and plated at 200-300,000 cells/well of a 6-well plate
in 2mLmTeSR1 with 2uM of Thiazovivin. The Gorlin iPSC (male Gorlin 1 derived from KAS537 keratinocytes, female Gorlin 2 derived
from KAS573 keratinocytes) and female control (derived from KTM1 keratinocytes) were maintained on MEF feeders in KSRmedium
(DMEM/F12, knockout serum replacement (KSR) 20%, L-glutamine 2mM, NEAA (0.1mM), 2-mercaptoethanol (0.1mM) supple-
mented with FGF2 (10ng/ml). The iPSC colonies were passaged 1:3 every 4-5 days using dissociation buffer (1mM calcium chloride,
0.025% trypsin, 1mg/ml collagenase IV, 1:5 KSR media, made in PBS solution). Gorlin iPSC were authenticated by Sanger
sequencing of genomic DNA for PTCH1 at c.G1762 (Gorlin 1) and c.C1925 (Gorlin 2). All experiments using iPSC in the William A
Weiss lab (UCSF) were approved by Human Gamete, Embryo and Stem Cell Research Committee of the UCSF Stem Cell Research
Oversight Committee. All experiments using iPSC in the Austin Smith lab (University of Cambridge) were performed under ethical
approval from the Cambridgeshire Research Ethics Committee (Reference 96/085). The storage and use of human tissue was
approved by the Human Tissue Authority, UK (License number 12196). Although we observed a difference in tumorigenic penetrance
using a male (Gorlin 1) and female (Gorlin 2) NES cells (Figure 4B), this is likely due to differences in transcriptomes unrelated to the
sex identity.
METHOD DETAILS
Gorlin iPSC derivation
Gorlin (KAS537, KAS573) and normal human keratinocytes (KTM1) were obtained from patients and healthy controls respectively as
previously described (Hovestadt et al., 2013; Sturm et al., 2012). Primary human adult keratinocytes obtained from Thierry
Magnaldo’s laboratory were cultured in recombinant human collagen type I- plated tissue culture flasks in EpiLife Medium supple-
mented with EpiLife Defined Growth Supplement (EDGS). Transgene-free reprogramming of keratinocytes to iPSCwas achieved us-
ing Sendai virus (SeV), a negative sense single-stranded RNA virus that replicates in the cytoplasmwithout a DNAphase (Fusaki et al.,
2009). In brief, approximately 5 3 104 to 10 3 104 keratinocytes were seeded per well of a six well plate in EpiLife media supple-
mented with EDGS. Each well was then infected with separate SeV constructs carrying the pluripotency genes Oct4, Klf4, Sox2
and c-Myc at a multiplicity of infection (MOI) of 5 for 24 hours in 1ml EpiLife media per well. Virus containing media was removed
and the cells were washed gently twice with PBS and replaced with fresh Epilife media. On day 4 post-infection, keratinocytes
were collected, counted and seeded at a density of 43 105 initially in EpiLife media on inactivated MEFs. Epilife media was replaced
with KSR medium supplemented with FGF2 (10ng/ml) after a further 24 hours. KSR/FGF2 media was changed every two days and
pluripotent stem cell colonies emerged after 4-6 weeks. Keratinocyte derived iPSC were picked and expanded on MEF feeders in
KSR/FGF2 media. Informed consent was obtained from all subjects.e4 Cell Stem Cell 25, 433–446.e1–e7, September 5, 2019
Teratoma formation assay
Human iPSC were injected into the kidney capsule of NOD/SKID mice using a protocol adapted from (Morris et al., 2014). Mice were
sacrificed after 3 months, or when the mice developed a visible abdominal mass. The teratomas were fixed with 10% formalin and
prepared for paraffin embedded sections.
Embryoid body formation and differentiation
iPSC colonies were floated in KSRmedia (without FGF2) on untreated tissue culture plates at 37 degrees for 1-2 weeks. The embryoid
bodies were then plated on tissue culture flasks coatedwith poly-L-ornithine and laminin in N2B27media (1:1 Neurobasal:DMEM/F12,
L-glutamine 2mM, N-2 supplement 0.5x, B27 w/o vitamin A supplement 0.5x, 2-mercaptoethanol (0.1mM)) for further 1-2 weeks.
Differentiation to and maintenance of neuroepithelial stem (NES) cells
iPSC differentiation to NES cells was performed as previously described (Koch et al., 2009). Briefly, iPSC were cultured as
embryoid bodies in KSR medium with SB431542 (10uM), LDN193189 (500nM) for 3 days, N2 medium (DMEM/F-12 (0.5x) & Neuro-
basal medium (0.5x), N2 supplement (0.5x), B27 supplement (0.5x)) for 6 days and plated on poly-L-ornithine/laminin coated plates
for another 6 days in N2 medium. Rosettes were picked, dissociated in Accutase for 5 min at 37C and plated on poly-L-ornithine/
laminin coated wells in NES cell medium (DMEM/F-12, Glutamax, 1x N2 supplement, 0.05x B27 w/o vitamin A supplement, 1.6g/L
Glucose, 10-20ng/mL EGF, 10-20ng/mL FGF2) in a humidified 37C incubator with 5% CO2. NES cells were fed daily and passaged
every 3-4 days using TrypLE Express and plated at 500-600,000 cells/well of a 6-well plate in 2mL NES cell medium.
Spontaneous and direct differentiation of NES cells
NES cells were differentiated spontaneously or directly in Figure 5. For spontaneous differentiation, NES cells were cultured in N2
medium for 2 days. For direct differentiation, NES cells were grown in N2 medium supplemented with Wnt3a (20ng/mL) and
GDF7 (100ng/mL) for 2 days.
CRISPR plasmid and mutation detection
sgRNA targeting GSE1 and KDM3B were designed using http://crispor.org and cloned into pLentiCRISPR v2. After NES cells were
transduced with plasmids encoding Cas9 and sgRNA, we selected the cell population with puromycin. Genomic DNAwas extracted,
and PCRwas performed across the targeted junction using Accuprime HiFi Taq. Primers for sgRNA and PCRwere obtained from IDT
Technologies. PCR products were digested using Surveyor Nuclease mutation detection kit and visualized on 10% TBE gels stained
in GelRed. To identify mutations and quantitate efficiency ofmutations, amplicon sequencing was performed using services provided
by GENEWIZ (https://www.genewiz.com/en).
Karyotype analysis
G-band karyotype analysis of NES cells were analyzed by Cincinnati Children’s Hospital (https://www.cincinnatichildrens.org/
service/d/diagnostic-labs/cytogenetics),
RT-qPCR
RNA was extracted using an RNA extraction kit (Zymo Research). 500ng of RNA was converted to cDNA using Vilo Superscript
(Thermo Fisher) in a 20uL final volume and the following settings: 25C for 10min, 42C for 60 min and 85C for 5 min. cDNA was
then diluted in 80uL of water and qPCR was performed in a 384 well plate using SYBR green (KAPA Biosystems) on an
AB7900HT machine with the following settings: 95C for 1 min, 40 cycles (95C for 3 s and 60C for 1 min). Each qPCR reaction
occurred in final volume of 10uL containing 5uL SYBR mastermix, 5uM of each forward and reverse primer, and 0.4uL of the
cDNA. Gene expression was normalized to GAPDH and represented as fold increase over control cell lines.
Cell proliferation assays
EdU andCyQuant Direct cell proliferation kits were used according tomanufacturer protocol. For EdU assays, cells were treated with
10uM EdU for 1hours, fixed and undergone Click-iT chemistry to stain for EdU in cells. Subsequently, cells were counterstained in
DAPI and run on BD FACSAria III to obtain the cell populations in G1, S andG2/M phase. For CyQuant Direct, cells were plated on 3-4
poly-l-ornithine/laminin coated 96 well plates at 20,000 cells per well. Each day, one plate was fixed and stained using the CyQuant
Direct nucleic acid stain and background suppression dye and analyzed on a plate reader for green fluorescence in the nucleic acid
stain. Raw data was normalized to Day 1 measurements to determine the percentage of increase in cells on subsequent days.
RNA-seq
Total RNAwas extracted from flash frozen tissue using a AllPrep DNA/RNAMini Kit. Quality of total RNA samples was checked on an
Agilent Bioanalyzer 2100 RNA Nano chip (Agilent). RNA samples with RNA Integrity Numbers of at least 7 were sent to Novogene
(https://en.novogene.com/) for library preparation (polyA enrichment) and RNA sequencing (150 base pair Paired End reads,
50 million reads total).Cell Stem Cell 25, 433–446.e1–e7, September 5, 2019 e5
Differential gene expression analysis of NES cells and tumors derived from NES cells
To examine transcriptomic differences, cDNA reads were aligned to hg19 using STAR alignment(v2.6.1) to generate bam files (Dobin
et al., 2013). Unnormalized gene read counts were generated using STAR. Differentially expressed genes were normalized and
analyzed using the DESeq2(v1.22.1) package in R(v3.5.1) (Love et al., 2014).
Comparison of transcriptomes of tumors from NES cells with different brain tumor types and medulloblastoma
subgroups
Raw RNA-seq reads were mapped to the human genome assembly GRCh37/hg19 using STAR v2.5.3a. The alignment was per-
formed with a two-pass approach, where splice junctions discovered during a first alignment guide the forming of a final second
alignment. Finally, reads unmapped by STAR were subjected to a final round of alignment via bowtie2 2.3.4.3 (Langmead and Salz-
berg, 2012). Read counts for geneswere extracted using the featureCounts function from the subread 1.5.2 package and utilizing h19
gene annotations from GENCODE (Liao et al., 2013). Subsequently, read counts were converted to measures of transcripts per
million (TPM). Ensembl gene ids were translated to official gene symbols (HUGO Gene Nomenclature Committee; HGNC) in R using
the biomaRt package (Durinck et al., 2005).
Microarray expression preprocessing
CEL files from three microarray expression datasets were downloaded from GEO: medulloblastoma samples with subgroup anno-
tation (GEO: GSE85217, 763 samples, (Cavalli et al., 2017)), brain tumors & normal brain (GEO: GSE50161, 130 samples, (Griesinger
et al., 2013)), GTML (GEO: GSE36594, 32 samples, (Swartling et al., 2012)). CEL files were preprocessed with the Robust Multichip
Average (RMA) protocol in the Affymetrix Expression Console (AEC). Gene symbols in the resulting gene expression matrix were
translated to official HGNC gene symbols and multiple rows associated with the same gene symbol were collapsed using the
average.
Cross-dataset classifications
Tumor sampleswere classified and comparedwith other brain tumors ormedulloblastoma subgroups in R using a package for cross-
platform comparisons of transcriptional profiles (Tamayo et al., 2007). Specifically, the script was employed using either the GEO:
GSE85217 or GEO: GSE50161 as model and then projecting the gene expression data of tumor samples onto these model data,
respectively. From the various outputs generated by the R package, we employed the hierarchical clustering plot, principal compo-
nent analyses plot, and results of the support vector machine classification in order to characterize our tumor samples.
Granular Neural Precursor (GNP) comparison
Raw single cell RNA-seq data of GNP cells from normal mouse cerebellum were obtained from ENA: PRJEB23051 (Carter et al.,
2018). Clusters 21 and 22 were found to be indicative of GNP cells and were subsequently compared to RNA-sequencing of our
NES cells. Differentially expressed genes were analyzed using the DESeq2(v1.22.1) package in R(v3.5.1) (Love et al., 2014). To ac-
count for the coverage difference in single cell versus bulk RNA-sequencing, we elected to not filter for coverage in GNP expression
comparisons.
Whole Exome Sequencing (WES) and variant discovery
Genomic DNA was isolated from tumors and NES cells using AllPrep DNA/RNA Mini Kit. Quality of genomic DNA was checked on a
1%agarose gel. Exome capture, library preparation andwhole exome sequencing (150 base pair Paired End reads at 100x coverage)
was conducted using Agilent SureSelect Human All Exon V6 Kit by Novogene (https://en.novogene.com/).
To examine genomic variants, exome paired-end reads were aligned to hg19/grch37 using BWA-MEM(v0.7.15) and sorted using
SAMtools to produced sorted-mapped bams (Li, 2013; Li et al., 2009). The sorted-mapped bams were processed by marking
duplicates and recalibrating bases using Picard tools(v2.18.25) (http://broadinstitute.github.io/picard/). Single nucleotide variants
and indels (insertions and deletions) were called using Mutect2(v4.1) and Varscan2(v2.4.3) following best practices (DePristo
et al., 2011; Koboldt et al., 2013; 2012; McKenna et al., 2010; Reble et al., 2017). Somatic variants were called using NES cells as
the normal sample and the transformed or implanted cells as the tumor sample. Tumor-only variants of each sample were also called
in tumor-only mode. Somatic and tumor-only variants were annotated using annovar(v.2015) (Wang et al., 2010). Population
frequency of each variant was gathered frommultiple databases (1000 Genomes Project Consortium et al., 2015; Horst, 2013; Karc-
zewski et al., 2019; Lek et al., 2016; Server and Project, 2013; Sherry et al., 2001).
Copy number variation analysis
DNAwas extracted from tumors and analyzed for genome-wide DNAmethylation patterns using the Illumina HumanMethylationEPIC
BeadChip (850k) array. Processing of DNA methylation data was performed with custom approaches as previously described
(Hovestadt et al., 2013; Sturm et al., 2012), and copy number profiles were generated using the ‘conumee’ package for R (https://
www.bioconductor.org/packages/release/bioc/html/conumee.html).e6 Cell Stem Cell 25, 433–446.e1–e7, September 5, 2019
Methylation array analysis
Raw methylation array data were processed, filtered, and normalized using the Chip Analysis Methylation Pipeline (ChAMP v. 2.6.4)
(Morris et al., 2014) within Bioconductor and in R (v. 3.3.3). Human cerebellum and human medulloblastoma tumors were processed
separately using 450K methods whereas iPSC-based tumors used EPIC methods. Overlapping normalized beta values from probes
that passed QC (n = 348,212) were combined from all groups. Differential methylation analysis was performed using metilene
(v. 0.26)(J€uhling et al., 2016) with a minimum CpG length of 10, a minimum absolute difference of 0.1, and adjusted p values < 0.05.
Overlapping DMRs were identified using the GenomicRanges package (v 1.26.4).
QUANTIFICATION AND STATISTICAL ANALYSIS
Mutational rate estimates
The mutational rate of the NES cell tumors were determined by extracting the nonsynonymous, synonymous, stop modulating,
somatic variants; these variants are further filtered by excluding variants found above 1% in population frequency databases
(1000 Genomes Project Consortium et al., 2015; Horst, 2013; Karczewski et al., 2019; Lek et al., 2016; Server and Project, 2013;
Sherry et al., 2001). Somatic variants were filtered for false positives by excluding variants with fewer than 10 reads and at a variant
allele frequency of 15% or lower. The mutational rate was estimated by dividing the remaining somatic variants by the size of the
exome (30 megabases).
Quantitation of IHC for p53 and FLAG-MYCN
For quantitation of nuclear p53 and FLAG-MYCN staining in IHC, the number of positive cells was divided by the number of total cells.
Positive and total cells were counted manually. A minimum of three fields of view were analyzed per tumor, with approximately
400 cells in each field of view. Data represent mean ± standard error of mean.
Statistical analysis
For qPCR, EdU andCyQuant Direct Cell proliferation assays, data points represent the average of 3 independent experiments ± stan-
dard error of mean and p values were generated by one-tailed t test (unequal variance) For survival curves, p values were calculated
by Log-rank (Mantel-Cox test) using GraphPad Prism. For all statistical analyses, p value less than 0.05 was interpreted as
statistically significant.
DATA AND CODE AVAILABILITY
Raw data for whole exome sequencing, RNA-seq and amplicon sequencing are stored in the European Genome Archive
(https://ega-archive.org). The accession number for the sequencing data reported in this paper is EGA: EGAS00001003620. Pre-
viously published datasets used are listed in the Key Resources Table.Cell Stem Cell 25, 433–446.e1–e7, September 5, 2019 e7
